About US
Contact us
-
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longerAstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partn2025/3/4
-
Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic strokeOver nearly the last three decades, Genentech has had the lone medicine on the market for the acute treatment of stroke. Monday, the Roche subsidiaryaddeda second stroke treatment to its repertoire,2025/2/28
-
Sinusitis data from Amgen, AZ's Tezspire spark 'best-in-disease' talk amid Sanofi, GSK competitionAlready billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic rhinosinusitis with nasal polyps (CRSwNP). Tezspire showed numerically better2025/2/28
-
Bristol Myers' cost-savings drive claims another 223 jobs in NJAs Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once again pruning its workforce in the Garden State. BMS will lay off 223 work2025/2/25
-
Roche touts head-to-head data for Xolair against oral immunotherapy for treating food allergiesA year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have pr2025/2/25
-
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nodNovo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing deal worth up to $1.3 billion. AstraZeneca is buying out its roxadustat part2025/2/20
-
Canada locks down an initial 500K doses of GSK's bird flu vaccineFollowing similar deals in countries like the U.S. and the U.K., Canada is bolstering its stockpile of bird flu vaccines and rolling out new guidance to ensure the shot reaches those who need it most2025/2/20
-
Merck, plaintiff agree to hit the brakes on Gardasil trial in CaliforniaLawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the li2025/2/18
-
FDA disrupts Harmony's expansion dreams for excessive sleepiness drug Wakix with refusal letterHarmony Biosciences is facing more of a nightmare than sweet dreams on the road to securing a new use for its excessive daytime sleepiness (EDS) med Wakix. The FDA promptly shot down the company’s bi2025/2/18
-
Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLCBristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it hasdeliveredan overall survival (OS) edge when added to chem2025/2/13